Juva Life Advances Intellectual Property Protection Program

Juva Life Inc., a California-based life sciences company, has advanced its intellectual property protection program and announced that its OTCQB-traded shares are now eligible for electronic settlement through The Depository Trust Company (DTC) in New York.

The company aims to protect its inventions through a combination of trade secrets for discovery technologies and patenting novel compositions and uses. Juva Life focuses on the research and development of cannabis products, specifically identifying products targeting inflammatory conditions. This initiative is led by the company's Vice President of Chemistry, Sanjeev Gangwar, who brings extensive experience from roles including Director of Oncology Discovery Chemistry for Bristol-Myers Squibb.

In addition, Juva Life is expanding its commercial trademarks. The company has filed applications for 24 trademarks across multiple classes and goods, including brand identity, messaging, and products. These filings span several jurisdictions, including the United States, Canada, the European Union, and globally through the World Intellectual Property Organization (WIPO).

Concurrently, the company announced that its U.S.-traded OTCQB shares are now DTC eligible. This allows for electronic clearing and settlement of its securities, speeding up the process for investors and brokers. This is expected to broaden the company's investor base and improve liquidity for its stock in the U.S. market.

Juva Life operates a comprehensive business model encompassing research, cultivation, manufacturing, retail, and delivery services. The company utilizes advanced tools in discovery, development, and data science to identify new molecular profiles for unmet medical needs, initially focusing on cannabis for consumer and pharmaceutical applications.